DrugPatentWatch Database Preview
Patent: 9,220,705
» See Plans and Pricing
Summary for Patent: 9,220,705
| Title: | Method of treating colorectal cancer |
| Abstract: | The present invention relates to the use of certain platinum compounds including [PtCl.sub.2(cis-1,4-diaminocyclohexane)], or combinations of these compounds with a variety of other agents for treating and/or preventing the progression of colorectal cancer in mammals. In particular, the invention provides methods of treating and/or preventing oxaliplatin-refractory colorectal cancer in mammals. |
| Inventor(s): | Hoeschele; James David (Plymouth, MI), Margiotta; Nicola (Barletta, IT), Gandin; Valentina (Tarzo, IT), Petruzzella; Emanuele (Molfetta, IT), Marzano; Cristina (Padua, IT) |
| Assignee: | |
| Application Number: | 14/199,858 |
| Patent Claims: | see list of patent claims |
Details for Patent 9,220,705
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech | AVASTIN | bevacizumab | VIAL; INTRAVENOUS | 125085 | 002 | 2004-02-26 | Start Trial | 2039-02-26 | RX | search | ||
| Genentech | AVASTIN | bevacizumab | VIAL; INTRAVENOUS | 125085 | 001 | 2004-02-26 | Start Trial | 2039-02-26 | RX | search | ||
| Imclone | ERBITUX | cetuximab | VIAL; INTRAVENOUS | 125084 | 001 | 2004-06-18 | Start Trial | 2039-02-26 | RX | Orphan | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patent Family for US Patent 9,220,705
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| United States of America | 2014255394 | Start Trial |
| United States of America | 2016096855 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
